Related Experiment Videos
Clinical interest of PPARs ligands
1Service d'Endocrinologie, Diabétologie et Maladies Métaboliques, hôpital du Bocage, CHU de Dijon, France. bruno.verges@chu-dijon.fr
Diabetes & Metabolism
|March 19, 2004
Summary
Peroxisome proliferator-activated receptors (PPARs) agonists, including PPARs alpha (fibrates) and PPARs gamma (glitazones), show promise in reducing cardiovascular disease in patients with metabolic syndrome and type 2 diabetes. These agents improve glucose and lipid metabolism, reduce inflammation, and enhance endothelial function.
Area of Science:
- Endocrinology and Metabolism
- Cardiovascular Medicine
- Pharmacology
Background:
- Metabolic syndrome and type 2 diabetes significantly elevate cardiovascular disease (CVD) risk.
- Chronic hyperglycemia, dyslipidemia, endothelial dysfunction, inflammation, oxidative stress, and altered coagulation contribute to CVD events in these patients.
Purpose of the Study:
- To evaluate the potential of Peroxisome proliferator-activated receptors (PPARs) agonists, specifically PPARs alpha (fibrates) and PPARs gamma (glitazones), in mitigating cardiovascular disease in individuals with metabolic syndrome or type 2 diabetes.
Main Methods:
- Review of existing clinical trial data and pharmacological mechanisms of PPARs alpha and PPARs gamma agonists.
- Analysis of effects on glucose homeostasis, lipid metabolism, inflammation, thrombosis, fibrinolysis, and endothelial function.
Main Results:
- PPARs alpha agonists (fibrates) improve lipid profiles (increase HDL, decrease triglycerides and LDL) and reduce vascular inflammation and thrombosis.
- PPARs gamma agonists (glitazones) enhance insulin sensitivity, improve glucose control, favorably alter lipid profiles, and reduce vascular inflammation and smooth muscle cell proliferation.
- Both agonist classes demonstrate positive effects on factors contributing to atherosclerosis and cardiovascular events.
Conclusions:
- PPARs alpha and PPARs gamma agonists are strong candidates for reducing cardiovascular disease in patients with metabolic syndrome and type 2 diabetes due to their multifaceted beneficial effects.
- Ongoing studies are crucial to fully elucidate the clinical benefits of PPARs gamma agonists in type 2 diabetic patients for cardiovascular disease reduction.